Dr. Gilchuk received his M.S. in Biochemistry, and doctorate in Biotechnology in 2007 from National Taras Shevchenko University of Kyiv, (Kyiv, Ukraine). His dissertation was focused on single-chain antibody design and discovery. After graduation, Dr. Gilchuk was working on both research and developmental projects, as a researcher and later as a group leader. From 2002 to 2009 Dr. Gilchuk was hired by former Phage Biotechnology Corporation (San Diego, CA) where he was advanced from Engineer Biologist to Research Group Manager. As a part of his effort, Dr. Gilchuk also occupied a staff scientist position at the Institute of Molecular Biology and Genetics NASU (Kyiv, Ukraine), and served as the laboratory head at the State Institute of Genetic and Regenerative Medicine AMSU (Kyiv, Ukraine). His work resulted in four Ukrainian declarative and one US inventory patents, as well as 11 primary research publications. In 2009 Dr. Gilchuk joined Dr. Joyce’s laboratory at Vanderbilt University. His research was focused on a large-scale vaccinia virus-derived T cell epitope discovery, elucidation of immunological properties of lung-resident memory CD8+ T cells (Mini-Sabbatical Award, Program in Immunology at Vanderbilt), and development of platforms for T cell-targeted mucosal vaccination, and resulted in twelve primary research publications, two reviews, and one book chapter. Dr. Gilchuk is now occupying a Senior Staff Scientist position in the laboratory of Dr. James E. Crowe, Jr. His current studies are focused on human antibody-mediated immunity against filoviruses, and methods development for rapid identification of therapeutic antibodies against viral diseases (DARPA’s Pandemic Protection Platform program). Dr. Gilchuk is a member of the American Association of Immunologists.